Cargando…
Pancreatic Cancer
Worldwide, there are an estimated 232, 000 new cases of pancreatic cancer annually. In the United States, it is the fourth leading cause of cancer death, and approximately 30,000 people die of pancreatic cancer each year. The disease is difficult to diagnose in its early stages, and most patients ha...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2010.
|
| Edición: | 1st ed. 2010. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-0-387-77498-5 | ||
| 003 | DE-He213 | ||
| 005 | 20220116083603.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2010 xxu| s |||| 0|eng d | ||
| 020 | |a 9780387774985 |9 978-0-387-77498-5 | ||
| 024 | 7 | |a 10.1007/978-0-387-77498-5 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Pancreatic Cancer |h [electronic resource] / |c edited by John P. Neoptolemos, Raul A. Urrutia, James Abbruzzese, Markus W. Büchler. |
| 250 | |a 1st ed. 2010. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Springer, |c 2010. | |
| 300 | |a eReference. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Epidemiology: world overview, risk factors, prospects for prevention -- Development and structure of pancreas -- Pathologic classification and biological behaviour of pancreatic neoplasia -- Developmental molecular biology of the pancreas -- Molecular pathology of precursor lesions of pancreatic cancer, pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN) -- Epigenetics: its fundamentals and applications to a revised comprehensive progression model for pancreatic cancer -- Molecular pathology of pancreatic neuroendocrine tumours MEN-1: gastrinomas, insulinoma, Non-Functioning Tumours, VIPoma, glucagonoma, Von Hippel-Lindau, Neurofibromatosis -- Sporadic neuroendocrine pancreatic tumours -- Molecular pathology of non-pancreatic cancer lesions: Ampullary cancer, intra-pancreatic bile duct cancer, and duodenal cancer -- Miscellaneous non-pancreatic non-endocrine tumours -- Novel molecular relationships between chronic pancreatitis and cancer -- Pancreatic cancer stem cells -- Cell cycle control: signalling pathways in pancreatic pathogenesis -- Apoptosis: signalling pathways in pancreatic pathogenesis -- EGFR: signalling pathways in pancreatic pathogenesis Pl3, Akt, lKK, Ras, Raf, MAPKK, ERK -- Hedgehog: signalling pathways in pancreatic pathogenesis -- Smad4/TGF-ß pathway: signalling pathways in pancreatic pathogenesis -- Notch signalling in pancreatic morphogenesis and pancreatic cancer -- Molecular characterization of pancreatic cell lines -- Mouse models of exocrine pancreatic cancer -- Principles and applications of microarray gene expression in pancreatic cancer -- Principles and applications of proteomics in pancreatic cancer -- Tumour-stromal interaction: invasion and metastases -- Genetic susceptibility, high risk groups, chronic and hereditary pancreatitis, familial pancreatic cancer syndromes -- Inherited endocrine pancreatic tumors associated with Multiple Endocrine Neoplasia Type 1 Von-Hippel-Lindau Syndrome, and Neurofibromatosis Type 1 -- Clinical decision making in pancreatic cancer -- Paraneoplastic syndromes -- Diagnostic and therapeutic response markers -- CT and fusion PET-CT Diagnosis, staging, and follow-up -- MRI and MRCP: diagnosis and staging of pancreatic cancer -- EUS Diagnosis and staging -- Laparoscopy and laparoscopic ultrasound: diagnosis and staging -- Overview of palliative management for pancreatic cancer -- Endoscopy -- Interventional radiology -- Role of palliative surgery in advanced pancreatic cancer -- Chemotherapy for advanced pancreatic cancer -- Developments in chemoradiation in advanced pancreatic cancer -- Surgical resection for pancreatic cancer -- Role of venous resection in pancreatic cancer surgery -- Pathological reporting and staging following resection -- Japanese Pancreas Society staging for pancreatic cancer -- Adjuvant chemotherapy in pancreatic cancer -- Case for adjuvant chemoradiation therapy for pancreatic cancer -- Case for neoadjuvant treatment in pancreatic cancer -- Borderline resectable disease -- Management of cystic neoplasms serous cystic neoplasms mucinous, cystic neoplasms, intraductal paillary mucinous neoplasms -- Laparoscopic surgery for pancreatic neoplasm -- Modern Japanese approach to pancreas cancer -- Development of novel biomarkers -- Inherited genetics of pancreatic cancer and secondary screening -- Gene therapy for pancreatic cancer -- Vaccine therapy and immunotherapy -- Emerging targets in pancreatic cancer.-. | |
| 520 | |a Worldwide, there are an estimated 232, 000 new cases of pancreatic cancer annually. In the United States, it is the fourth leading cause of cancer death, and approximately 30,000 people die of pancreatic cancer each year. The disease is difficult to diagnose in its early stages, and most patients have incurable disease by the time they present with symptoms. The overall 5-year survival rate for this disease is less than 5%. In organizing this handbook, Dr. Neoptolemos and his co-editors will produce a distinguished Major Reference Work devoted to pancreatic cancer. This handbook will have widespread appeal among clinicians, pathologists and basic scientists who are now struggling to understand this complex and rapidly expanding field. Because of the recent and vast growth in both the clinical and scientific research being done in pancreatic cancer (there is currently an unprecedented investment by academia and industry in this field), each researcher's knowledge of other specialty areas outside his or her own is now often quite limited. The aim of this book is to place these the tangible advances-those that are indispensable to all working on pancreatic cancer-readily at hand. The book will focus on advances that will not become dated, and the editors will choose authors who are the very best in each area. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Endocrinology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Endocrinology. |
| 700 | 1 | |a Neoptolemos, John P. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Urrutia, Raul A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Abbruzzese, James. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Büchler, Markus W. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eReference | |
| 776 | 0 | 8 | |i Printed edition: |z 9780387774978 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-0-387-77498-5 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXRB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Reference Module Biomedical and Life Sciences (SpringerNature-43744) | ||